Details
September 6 @ 10:30 – 11:30 CEST
Room 04
Supported By: an educational grant from Daiichi Sankyo, Inc.
Program Description
Join us to explore the evolving role of HER2-directed antibody drug conjugates (ADCs) in advanced NSCLC. Gain expert insights on biomarker-driven care, real-world integration, and practical strategies to improve patient outcomes—plus a live Q&A to address your clinical questions.
Speakers
Nicolas Girard MD, PhD
Paris Saclay University Institut Curie
Professor
Paris, France
Raffaele Califano MD
Division of Cancer Sciences The University of Manchester Department of Medical Oncology The Christie NHS Foundation Trust
Professor
Manchester, United Kingdom
Antonio Passaro MD, PhD
European Institute of Oncology
Doctor
Milan, Italy
